Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Vesting of both types of equity awards depends on recipients continuing to serve Ocular through the applicable vesting dates.

Rhea-AI Summary

Ocular Therapeutix (NASDAQ: OCUL) granted inducement equity awards to eight newly hired non-executive employees, effective November 2, 2026.

The grants include options to purchase up to 35,775 common shares and restricted stock units representing 11,725 common shares. The options carry a $6.73 exercise price per share, equal to the grant-date closing price on The Nasdaq Global Market, and a ten-year term. Options vest over four years; restricted stock units vest over three years. The awards were granted under the 2019 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4) as an inducement to accept employment.

Positive

• None.

Negative

• Minor point. Forward-looking: it has not happened yet and may not happen.Options for up to 35,775 common shares at $6.73 per share create potential dilution upon exercise.
• Minor point. Forward-looking: it has not happened yet and may not happen.Restricted stock units covering 11,725 common shares create potential dilution as awards vest.

Key Figures

Newly hired employees: 8 employees Stock options: Up to 35,775 shares Restricted stock units: 11,725 shares +4 more

Newly hired employees

8 employees

Recipients of inducement equity awards

Stock options

Up to 35,775 shares

Aggregate shares purchasable under the options

Restricted stock units

11,725 shares

Aggregate shares represented by the awards

Option exercise price

$6.73 per share

Equal to the closing price on the grant effective date

Option term

10 years

Term of each stock option award

Option vesting

25% after 1 year; remainder in equal monthly installments over 3 years

Subject to continued service through applicable vesting dates

Restricted stock unit vesting

3 years

Equal annual installments on the first, second, and third grant anniversaries

Historical Context

2 past events · Latest: Oct 09

2 events

1. Oct 09

   Inducement grants

   24h Move

   +0.4%

   Granted options for up to 70,150 shares and RSUs for 22,900 shares at a $7.25 exercise price.

2. Sep 18

   Inducement grants

   24h Move

   -1.5%

   Granted options for up to 64,850 shares and RSUs for 21,350 shares at a $10.72 exercise price.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

non-statutory stock option, restricted stock unit, nasdaq listing rule 5635(c)(4)

3 terms

non-statutory stock option financial

"consist of non-statutory stock option awards to purchase"

A non-statutory stock option is a company-granted right that lets a person buy shares later at a set price but does not receive special tax-favored treatment under tax law. It matters to investors because when the option is used the holder usually pays ordinary income tax on the gain and the company records compensation cost and issues new shares, which can reduce existing owners’ percentage ownership—think of it like a coupon to buy stock that creates a taxable event and some dilution.

restricted stock unit financial

"restricted stock unit awards representing the right to receive"

A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.

nasdaq listing rule 5635(c)(4) regulatory

"in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BEDFORD, Mass., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular” or the “Company”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it has granted inducement equity awards to eight newly hired non-executive employees. The awards were made as an inducement material to each recipient’s acceptance of employment with Ocular under Ocular’s 2019 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).

The inducement equity awards were granted effective as of November 2, 2026, and consist of non-statutory stock option awards to purchase up to an aggregate of 35,775 shares of Ocular’s common stock and restricted stock unit awards representing the right to receive an aggregate of 11,725 shares of Ocular’s common stock. The stock option awards have an exercise price of $6.73 per share, equal to the closing price of Ocular’s common stock on The Nasdaq Global Market on the effective date of grant. Each of the stock option awards has a ten-year term and vests over four years, with 25% of the original number of shares for each award vesting on the one-year anniversary of the applicable recipient’s commencement of employment, and the remainder vesting in equal monthly installments over the three years after such date, subject to the recipient’s continued service to Ocular through the applicable vesting dates. Each of the restricted stock unit awards vests over three years, in equal annual installments on the first, second and third anniversaries of the date of grant, subject to the recipient’s continued service to Ocular through the applicable vesting dates.

The inducement equity awards are subject to the terms and conditions of the award agreements covering the grants and Ocular’s 2019 Inducement Stock Incentive Plan.

About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. is an integrated biopharmaceutical company committed to redefining the retina experience. AXPAXLI™ (also known as OTX-TKI), Ocular’s investigational product candidate for retinal disease, is an axitinib intravitreal hydrogel based on its ELUTYX™ proprietary bioresorbable hydrogel-based formulation technology. AXPAXLI is currently in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), and diabetic retinal disease, including non-proliferative diabetic retinopathy (NPDR). Ocular’s pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA^®, an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery in adults and pediatric patients and ocular itching associated with allergic conjunctivitis in adults and pediatric patients aged two years or older, and in its investigational product candidate OTX-TIC, which is a travoprost intracameral hydrogel that has completed a Phase 2 clinical trial for the treatment of open-angle glaucoma or ocular hypertension. Ocular is currently evaluating next steps for the OTX-TIC program.

Follow the Company on its website, LinkedIn, or X.

DEXTENZA^® is a registered trademark of Ocular Therapeutix, Inc. The Ocular Therapeutix logo, AXPAXLI™, ELUTYX™, and Ocular Therapeutix™ are trademarks of Ocular Therapeutix, Inc.

Investors & Media
Ocular Therapeutix, Inc.
Bill Slattery
Vice President, Investor Relations
bslattery@ocutx.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What inducement equity awards did Ocular Therapeutix grant in November 2026?

Ocular granted eight newly hired non-executive employees options to purchase up to 35,775 common shares and restricted stock units representing 11,725 common shares, effective November 2, 2026. The options have an exercise price of $6.73 per share and a ten-year term.

How do Ocular Therapeutix's November 2026 inducement awards vest?

Options vest 25% on the first anniversary of each recipient's employment commencement, with the remainder vesting in equal monthly installments over the following three years. Restricted stock units vest in equal annual installments on the first, second and third grant-date anniversaries. Both schedules require continued service through the applicable vesting dates.